

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jin Xin Fertility Group Limited

錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 25, 2026

Reference is made to the circular of Jin Xin Fertility Group Limited (the “**Company**”) dated June 2, 2026 (the “**Circular**”) incorporating, amongst others, the notice (the “**Notice**”) of annual general meeting of the Company (the “**Annual General Meeting**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

At the Annual General Meeting held on June 25, 2026, all the proposed resolutions as set out in the Notice were taken by poll.

Mr. Dong Yang, Dr. Lyu Rong, Dr. Geng Lihong, Mr. Zhong Yong, Ms. Hu Zhe, Ms. Yan Xiaoqing, Mr. Chen Shuyun, Dr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing attended the Annual General Meeting either in person or by electronic means.

The Company’s Hong Kong share registrar, Computershare Hong Kong Investor Services Limited was appointed as the scrutineer at the Annual General Meeting for the purpose of vote-taking. The poll results in respect of the respective resolutions proposed at the Annual General Meeting were as follows:

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company for the year ended December 31, 2025 and the reports of the directors and auditor thereon.	252,628,640 99.872665%	322,094 0.127335%

* For identification purpose only

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
2.	To re-elect the following retiring directors of the Company, each as a separate resolution:		
	(i) Dr. Geng Lihong as an executive director.	250,591,075 99.067147%	2,359,659 0.932853%
	(ii) Ms. Yan Xiaoqing as a non-executive director.	250,591,075 99.067147%	2,359,659 0.932853%
	(iii) Dr. Chong Yat Keung as an independent non-executive director.	251,844,871 99.562815%	1,105,863 0.437185%
	(iv) Mr. Wang Xiaobo as an independent non-executive director.	251,832,686 99.557998%	1,118,048 0.442002%
3.	To authorize the board of directors of the Company (the “ Board ”) to fix the remuneration of the directors of the Company (the “ Directors ”).	251,852,833 99.565963%	1,097,901 0.434037%
4.	To declare a final dividend of HK\$4.18 cents per share for the year ended December 31, 2025.	252,925,234 99.989919%	25,500 0.010081%
5.	To re-appoint Deloitte Touche Tohmatsu as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending December 31, 2026.	202,785,966 80.168167%	50,164,768 19.831833%
6(A).	To grant a general mandate to the Directors to exercise the powers of the Company to allot, issue and deal with additional shares (including any sale or transfer of treasury Shares) not exceeding 20% of the total number of issued shares of the Company (excluding any treasury Shares and shares repurchased but not cancelled) as at the date of passing of this resolution.	150,235,102 59.393029%	102,715,632 40.606971%
6(B).	To grant a general mandate to the Directors to exercise the powers of the Company to repurchase shares representing up to 10% of the total number of issued shares of the Company (excluding any treasury Shares and shares repurchased but not cancelled) as at the date of passing of this resolution.	252,925,234 99.989919%	25,500 0.010081%
6(C).	To extend the general mandate granted to the Directors to allot, issue and deal with shares by the number of shares repurchased by the Company under ordinary resolution 6(B).	150,235,102 59.393029%	102,715,632 40.606971%

Notes:

- (1) As at the date of the Annual General Meeting, the total number of Shares in issue was 2,705,044,043 Shares and among which (i) there were no treasury Shares held by the Company and (ii) there were 79,924,500 repurchased Shares which are pending cancellation and should be excluded from the total number of Shares in issue for the purpose of the AGM. The Company confirmed that no voting rights of the 79,924,500 repurchased Shares which are pending cancellation have been exercised at the AGM.
- (2) There was no Shares entitling the Shareholders to attend and vote only against the proposed resolutions at the Annual General Meeting. No party has stated its intention in the Circular that it would vote against any proposed resolution or that it would abstain from voting at the Annual General Meeting.
- (3) As at the date of the Annual General Meeting, the trustees of the Pre-IPO RSU Scheme, the 2022 Share Award Scheme and the 2025 Share Scheme (the “**Trustees**”) held in aggregate 59,569,404 Shares, being unvested Restricted Shares granted thereunder.

Save for the Trustees who were required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders’ approval under the Listing Rules, no other Shareholder was required to abstain from voting in respect of any resolution at the Annual General Meeting.

- (4) The total number of Shares entitling the holders thereof to attend and vote for or against the resolutions proposed at the Annual General Meeting was 2,565,550,139 Shares.
- (5) Please refer to the Notice for the full text of the resolutions.

As more than 50% of votes were cast in favor of each of the ordinary resolutions numbered 1 to 6, all of the above ordinary resolutions were duly passed at the Annual General Meeting.

By order of the Board
Jinxin Fertility Group Limited
Dong Yang

*Chief Executive Officer, Acting Chief Financial Officer
and Executive Director*

Hong Kong, June 25, 2026

As at the date of this announcement, the Board comprises Mr. Dong Yang, Dr. Lyu Rong and Dr. Geng Lihong, as executive directors; Mr. Zhong Yong, as chairman and non-executive director, and Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive directors; and Dr. Chong Yat Keung, Dr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive directors.